Humacyte, Inc. (NASDAQ:HUMA) Receives $8.14 Average PT from Brokerages

Shares of Humacyte, Inc. (NASDAQ:HUMA) have earned an average rating of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $8.1429.

HUMA has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of Humacyte in a report on Monday, December 1st. UBS Group restated a “buy” rating on shares of Humacyte in a research note on Monday, December 1st. Benchmark reduced their price target on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, January 21st. BTIG Research reissued a “buy” rating and set a $6.00 price objective on shares of Humacyte in a report on Monday, February 9th. Finally, Wall Street Zen downgraded shares of Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday, December 21st.

Institutional Trading of Humacyte

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Humacyte by 7.4% in the third quarter. Vanguard Group Inc. now owns 7,520,055 shares of the company’s stock worth $13,085,000 after purchasing an additional 520,431 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Humacyte by 20.2% during the 4th quarter. Geode Capital Management LLC now owns 3,720,436 shares of the company’s stock valued at $3,574,000 after purchasing an additional 624,220 shares during the last quarter. CenterBook Partners LP lifted its stake in shares of Humacyte by 141.1% in the 2nd quarter. CenterBook Partners LP now owns 3,430,255 shares of the company’s stock worth $7,169,000 after purchasing an additional 2,007,743 shares during the period. UBS Group AG boosted its holdings in shares of Humacyte by 48.8% in the fourth quarter. UBS Group AG now owns 2,978,610 shares of the company’s stock worth $2,862,000 after buying an additional 976,275 shares during the last quarter. Finally, State Street Corp grew its position in Humacyte by 17.8% during the fourth quarter. State Street Corp now owns 2,837,276 shares of the company’s stock valued at $2,725,000 after buying an additional 429,233 shares during the period. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Stock Performance

HUMA stock opened at $1.14 on Tuesday. The stock’s 50 day simple moving average is $1.06 and its 200 day simple moving average is $1.38. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97. Humacyte has a 12-month low of $0.88 and a 12-month high of $3.94. The stock has a market capitalization of $213.49 million, a PE ratio of -4.96 and a beta of 1.93.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.